Renal and Inflammatory Proteins as Biomarkers of Diabetic Kidney Disease and Lupus Nephritis

Nathan H. Johnson, Robert W. Keane, and Juan Pablo de Rivero Vaccari

Department of Physiology and Biophysics, University of Miami Miller School of Medicine, Miami, FL, USA
Department of Neurological Surgery and The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, FL, USA

Correspondence should be addressed to Juan Pablo de Rivero Vaccari; jderivero@med.miami.edu

Received 29 December 2021; Revised 13 February 2022; Accepted 19 February 2022; Published 19 March 2022

1. Introduction

Kidney disease is a major health concern impacting more than 750 million people throughout the world and represents a significant burden to patients and health care systems [1]. Kidney disease is a generalized term representing an assortment of disorders impacting the renal system, each with complex and often uniquely distinctive pathologies [2]. Currently, the most widely used method for the diagnosis of kidney disease is through the measurement of the glomerular filtration rate (GFR) [2, 3]. Although long considered a “golden standard” for the detection of kidney disorders, a patient’s GFR is typically determined by measuring the concentrations of kidney filtrates in blood plasma or in urine [3]. Since the GFR is the collective product of millions of glomeruli working concurrently, a patient’s true GFR is often very difficult to establish [3]. Clinicians traditionally calculate an estimated glomerular filtration rate (eGFR) through measurement of serum creatinine and blood urea nitrogen (BUN) concentrations [2, 3]. Urinalysis may also be used to calculate a measured glomerular filtration rate (mGFR) by quantifying clearance of a readily filtered, exogenous substance such as inulin. Urinalysis is also used to detect proteinuria and to determine the albumin levels [2, 3]. Unfortunately, these methods traditionally used to determine GFR are nonspecific to the underlying cause of pathology and are often not significantly altered until much later in disease progression [2–4].

Of the kidney diseases, diabetic kidney disease (DKD) and lupus nephritis (LN) are two chronic disorders that
are typically not detected by altered GFR or proteinuria until much later in their development [4, 5]. In diabetic patients, DKD diagnosis is traditionally made when one or more of the following signs is present over a span of three months: a decreased eGFR (<60 ml/min/1.73 m²), an increase in daily albumin excretion in urine (≥30 mg), or an increase in the urinary albumin/creatinine ratio (≥30 mg g⁻¹) [5]. In patients suffering from systemic lupus erythematosus (SLE), the development of LN is determined by increased protein in urine (>0.5 g daily), from the presence of cellular casts in urine, or from an increased urinary creatinine/protein level (>0.5) [6]. Additionally, LN may be diagnosed through renal biopsy. However, this method is invasive and potentially hazardous [4, 6]. Although DKD and LN are two different disorders, they share many pathological attributes that are seen in almost every kidney disorder. Specifically, both disorders are known to cause increased expression of inflammatory proteins within the kidneys through activation of the inflammasome [7, 8].

The inflammasome is a multiprotein structure that allows for the assembly of inflammatory caspases and subsequent activation of cytokines to signal inflammation and cell death in native and neighboring cells [7, 9]. In cases of acute kidney injury and chronic kidney disease, the inflammasome has demonstrated a significant role in pathological development, as studies interfering with inflammasome activity have shown reduction in or regulation of pathological progression [8]. In DKD, studies have shown increased nucleotide binding domain- (NOD-) like receptor protein 3 (NLRP3) and absent in melanoma 2 protein (AIM2) expression within the kidneys and increased expression of the inflammatory cytokine interleukin-(IL-) 1β in serum [7]. In LN, studies have shown increased expression of NLRP3, caspase 1, and IL-1β in tissue collected by kidney biopsies and in podocytes [7, 10]. Thus, these studies show that the inflammasome has a promising target for the development of future therapeutics for renal diseases. Moreover, inflammasome proteins have been shown to be biomarkers of the inflammatory response associated with diagnosis of traumatic brain injury [11–14], stroke [15], depression [16], multiple sclerosis [17], mild cognitive impairment [18], Alzheimer’s disease [18], nonalcoholic steatohepatitis [19], psoriasis [20], and age-related macular degeneration [21].

Identification of biomarkers involved in renal pathology has the potential to be used to monitor disease progression in patients newly diagnosed with diabetes or lupus so that more personalized treatment strategies may be utilized. Moreover, inflammasome proteins can also be used as theragnostic biomarkers to identify whether patients are responding positively or negatively to different treatment strategies. The purpose of this study was to investigate biomarkers of renal disease independently of whether the disease has an autoimmune origin or a chronic disease known to affect the kidneys. Moreover, considering the multifactorial aspects that contribute to renal diseases, in this study, we analyzed a combination of kidney disease-associated proteins (Lipocalin/NGAL, EGF and uPA), as well as proteins associated with inflammasome activity (ASC and IL-18) and general inflammation (CRP) with the aim of determining their reliability as potential biomarkers of kidney disease, specifically, DKD and LN.

2. Materials and Methods

2.1. Participants. Serum from patients with DKD and LN (Table 1) and age-matched controls were obtained from BiolVT (Hicksville, NY). Donor informed consent was provided by those participating in the study Prospective Collection of Samples for Research funded by SeraTrials, LLC. with IRB number 20170439. Age-matched control samples were obtained from patients with no medical diagnosis of any disease with a median of 50 years old, a mean of 49.02, and a range between 21 and 101. Patients in the DKD group had a median age of 62 years old and a range between 21 and 90, and those with LN had a median age of 43.5 and a range between 19 and 75. Patients in the DKD cohort consisted of 17 Caucasians, 10 of African descent, and 4 of other race, whereas in the LN group there were 17 Caucasians, 11 of African descent, and 4 of other races. Patients with DKD presented the following comorbidities: hypertension (23 patients), hypercholesterolemia, (6 patients) hypothyroidism (8 patients), gastroesophageal reflux disease (7 patients), and coronary artery disease (7 patients), whereas patients in the LN group presented with Hypertension (6 patients), gastroesophageal reflux disease (2 patients), and coronary artery disease (3 patients).

DKD patients were characterized by a cohort representing 4 of the 5 stages of the disease as determined by the eGFR in ml/min/1.73 m²: 2 (guarded: 60–89), 3 (elevated: 30–59), 4 (high: 15–29), and 5 (severe: <15 or dialysis) [22]. Moreover, LN patients were in part diagnosed by kidney biopsy representing the following classifications: 2 (mesangial proliferative LN), 3 (focal LN affecting less than 50% of glomeruli), 4 (diffuse LN affecting more than 50% of glomeruli), and 5 (advanced sclerosing LN) [23].

In summary, in this proof-of-concept study, the inclusion/exclusion criteria were characterized by including patients with a positive diagnosis of either DKD or LN without an exclusion for age, race, or disease stage. Patients were included in the DKD cohort regardless of whether patients presented with either type I or type II diabetes. Due to the effects of DKD and LN on the renal system, patients with hypertension with a positive diagnosis for either DKD or LN were also included in the study. However, not having a diagnosis of HTN was not considered an excluding factor.

2.2. Simple Plex Assay. Concentration of inflammasome proteins (ASC and IL-18) and indicators of renal function (uPA, EGF, and Lipocalin/NGAL) and generalized inflammation (CRP) were measured in patients with DKD, LN, and in age-matched controls via Ella (Protein Simple) according to manufacturer instructions. Briefly, samples were diluted in diluent buffer and 50 μl of the sample was loaded on each well of a CART, and 1 ml of washing buffer was added to the respective well. Samples were then run in triplicates using a microfluidics system proprietary of the Ella Instrument (Protein Simple). Sample analysis was automatically
generated utilizing the Simple Plex Runner Software as described in [9].

2.3. Statistical and Biomarker Analyses. All samples were run for the expression of all analytes. Samples included in the analysis were only those that were within the lower and upper limit of detection for each analyte. Samples that presented protein levels outside the limit of detection of the assay for each analyte were dropped for such analyte. In addition, outliers were removed prior to further statistical analyses using the Robust regression and outlier removal (ROUT) method with a Q set to 1%. Differences between patient groups were tested by one-way ANOVA followed by Tukey’s multiple comparison test. Significance was set at \( p < 0.05 \). Simple Plex data from DKD, LN, and control samples were analyzed utilizing Prism 9 software (GraphPad). Specificity, sensitivity, confidence interval (95%), standard deviation, \( p \) value, and likelihood ratio was identified through calculation of receiver operating characteristics (ROC) and the total area under the curve (AUC). Additionally, cut-off points and positive and negative predictive values were calculated along with overall assay accuracy. The cut-off point for each analyte was chosen based on the highest likelihood ratio in the sensitivity vs. 1-specificity plot, considering a higher sensitivity than higher specificity values, in order to obtain assays that provide a higher likelihood of reliability for the respective sensitivity for each analyte [24]. In addition, a two-tailed Pearson \( r \) correlation matrix was carried using Prism 9 software (GraphPad). Sample size in this study was calculated by power analysis with the power set to 0.8 and considering the standard deviation and the difference between the means to obtain a significance of 0.05 for each analyte.

Combination of biomarkers was achieved by fitting a logistic regression model to explain the diagnosis of either DKD or LN followed by calculation of the AUC using RStudio (version 1.2.5033).

ROC curve comparison between analytes was done as described in [25] using the following formula to obtain a critical ratio \( Z \):

\[
Z = \frac{(A_1 - A_2)}{\sqrt{SE_1^2 + SE_2^2 - 2rSE_1SE_2}}.
\]

And the \( p \) value was determined using the following formula using Microsoft Excel (version 16.57):

\[
= 2 \times (1 - \text{NORMSDIST}(z))
\]

3. Results

3.1. ASC and IL-18 Is Elevated in the Serum of Patients with DKD and LN. The inflammasome has been previously shown to be involved in the pathology of renal diseases [26]. To determine the levels of the inflammasome signaling proteins, ASC and IL-18, serum from DKD and LN patients, were analyzed and compared to age-matched healthy controls for the expression of ASC (Figure 1(a)) and IL-18 (Figure 1(b)) proteins. ASC and IL-18 proteins were shown

| Table 1: Patients with DKD and lupus nephritis used in the study. |
|-----------------|-----------------|
| DKD patients    | 31              |
| LN patients     | 32              |
| Sex (DKD)       | Males (55%)–female (45%) |
|                 | 17 - 14         |
| Sex (LN)        | Males (25%)–female (72%)–unspecified (3%) |
|                 | 8–23–1          |
| Race (DKD)      | Caucasian       |
|                 | 17 (55%)        |
|                 | African         |
|                 | 10 (32%)        |
|                 | Other           |
|                 | 4 (13%)         |
| Race (LN)       | Caucasian       |
|                 | 17 (53%)        |
|                 | African         |
|                 | 11 (34%)        |
|                 | Other           |
|                 | 4 (13%)         |
| Age range (DKD) | Range 21 - 90   |
|                 | Median 62       |
|                 | Mean 63.32      |
| Age range (LN)  | Range 19 - 75   |
|                 | Median 43.5     |
|                 | Mean 44.91      |
| Comorbidities (DKD) | HTN 23 (74%) |
|                 | Hypercholesterolemia 6 (19%) |
|                 | Hypothyroidism 8 (26%) |
|                 | GERD 7 (23%)    |
|                 | CAD 7 (23%)     |
|                 | Diabetes type I 2 (6%) |
|                 | Diabetes type II 21 (68%) |
|                 | Diabetes (type unspecified) 8 (26%) |
| Comorbidities (LN) | HTN 6 (19%) |
|                 | GERD 2 (6%)     |
|                 | CAD 3 (9%)      |
| Disease stage (DKD) | 2 1 (3%) |
|                 | 3 7 (22%)      |
|                 | 4 2 (7%)       |
|                 | 5 2 (7%)       |
|                 | Unspecified 19 (61%) |
| Disease stage (LN) | 1 4 (12%) |
|                 | 3 6 (19%)      |
|                 | 4 5 (16%)      |
|                 | 5 2 (6%)       |
|                 | Unspecified 15 (47%) |

HTN: hypertension; GERD: gastroesophageal reflux disease; CAD: coronary artery disease.
to be significantly elevated in both DKD and LN patients compared to healthy controls. These results suggest that innate immune inflammatory activity is present in the pathology of both DKD and LN.

3.2. Biomarkers of Renal Disease Are Elevated in the Serum of DKD and LN Patients. CRP is a well-known biomarker of general inflammation. Similarly, uPA, EGF, and Lipocalin-2 have demonstrated involvement in the pathology of renal disease [27]. We analyzed serum of patients with DKD and LN for the expression of CRP (Figure 1(c)), uPA (Figure 1(d)), EGF (Figure 1(e)), and Lipocalin-2/NGAL (Figure 1(f)). Levels of CRP were higher in the LN group and not in the DKD group, whereas levels of uPA were higher in the DKD group but not in the LN group. Protein levels of EGF and Lipocalin-2/NGAL were higher in both groups when compared to the control group. Thus indicating that in this cohort of patients, there is a renal dysfunction consistent with the diagnosis of chronic renal diseases.

3.3. Biomarkers of DKD. To assess if the tested proteins could be reliable biomarkers of DKD, the area under the curve (AUC) was calculated for each protein of interest (Table 2). Of the proteins of interest, EGF (Figure 2(e)) and Lipocalin/NGAL (Figure 2(f)) were shown to have the highest AUC, 0.9935 and 0.9554, respectively, followed by ASC, 0.7666 (Figure 2(a)); uPA, 0.7522 (Figure 2(d)); and IL-18, 0.6849 (Figure 2(b)). The AUC for CRP, 0.6254 (Figure 2(c)) was not significant. Sensitivity of Lipocalin-2 was 100%, with an 83% specificity and a cut-off point of 10,187 pg/ml. Similarly, for EGF, sensitivity was 100% with a 94% specificity and a cut-off point of 27.99 pg/ml. With a cut-off point of 632 pg/ml, the sensitivity for ASC was 89% with a 63% specificity (Table 3). These findings indicate that EGF, Lipocalin-2/NGAL, ASC, uPA, and IL-18 can be used as part of a biomarker panel to diagnose DKD.

3.4. Biomarkers of LN. To assess if the tested proteins could be reliable biomarkers of LN the area under the curve (AUC) was calculated for each protein of interest (Table 2). Of the proteins of interest, EGF (Figure 3(e)) and Lipocalin/NGAL (Figure 3(f)) were shown to have the highest AUC of 1.00 and 0.9412, respectively. The AUC for CRP, 0.6526 (Figure 3(a)); for uPA, 0.7443 (Figure 3(d)); for IL-18, 0.7384 (Figure 3(b)); and for CRP, 0.6844 (Figure 3(c)). Sensitivity of Lipocalin-2 was 88%, with an 83% specificity and a cut-off point of 10,187 pg/ml. Similarly, for EGF, the sensitivity was 100% with a 100% specificity and a cut-off point of 38.53 pg/ml. For uPA, the cut-off point was 890.3 pg/ml with an 84% sensitivity and a 65% specificity, whereas with
and we found that in DKD patients the AUC was significantly different when comparing ASC with EGF ($p = 2.12E - 05$), ASC with NGAL ($p = 0.0009$), CRP with EGF ($p = 0.03$), CRP with NGAL ($p = 2.29E - 06$), uPA with EGF ($p = 0.001$), and uPA with NGAL ($p = 0.003$) (Supplementary Table 1), indicating that based on the AUC, in DKD, NGAL as a biomarker is consistently different to several of the other biomarkers analyzed. Similarly, when comparing the AUC for biomarkers in LN patients, the significant difference between curves was detected when comparing ASC with EGF ($p = 3.07E - 08$), IL-18 with EGF ($p = 9.45E - 06$), CRP with EGF ($p = 7.08E - 06$) and uPA with EGF ($0.0004$) (Supplementary Table 2), indicating that in LN based on the AUC, EGF as a biomarker is consistently different to several of the other biomarkers analyzed.

In addition, we combined biomarkers that presented lower AUC values with those present in EGF and NGAL to determine if a combination of biomarkers would increase the AUC value. Accordingly, when combining ASC, IL-18, and uPA, we found that the AUC for the diagnosis of DKD, increased to 0.82, and this value was higher than the AUC obtained for each biomarker alone (0.77, 0.68, and 0.75, respectively). Similarly, for the diagnosis of LN, we combined IL-18 and uPA to obtain an AUC of 0.81 that was also higher than the AUC obtained for each of those two biomarkers alone (0.74).

### 3.5. Correlation between DKD Biomarkers

To determine the correlation across serum levels of ASC, IL-18, CRP, uPA, EGF, and NGAL, in DKD patients, a Pearson $r$ correlation matrix was carried out (Figure 4). The greatest positive correlation was found between NGAL and EGF with an $r = 0.74$ ($p = 1.44E - 05$) followed by EGF and IL-18 with an $r = 0.50$ ($p = 0.002$) and NGAL and uPA ($r = 0.43$, $p = 0.011$). The correlation between ASC and IL-18 was 0.39 ($p = 0.00073$) and between ASC and EGF was 0.37 ($p = 0.036$), indicating common trends in the expression between the proteins analyzed in this study in the serum of DKD patients.

### 3.6. Correlation between LN Biomarkers

To determine the correlation across serum levels of ASC, IL-18, CRP, uPA, EGF, and NGAL in LN patients, a Pearson $r$ correlation matrix was carried out (Figure 5). The greatest positive correlation was found between NGAL and uPA with an $r = 0.48$ ($p = 0.003$) followed by EGF and NGAL ($r = 0.45$, $p = 0.014$). The correlation between ASC and CRP was $r = 0.39$ ($p = 0.001$), and between NGAL and CRP the correlation was $r = 0.37$ ($p = 0.03$), indicating common trends in the expression between the analyzed proteins in the serum of LN patients.

### 4. Discussion

DKD and LN are chronic renal disorders associated with kidney damage resulting from inflammation. In this study, we show an array of renal and inflammasome proteins that are not only elevated but are also reliable biomarkers of both disorders. In the serum of DKD and LN patients, we determined an increased expression of the inflammasome.
scaffolding protein ASC and increased levels of the proinflammatory cytokine IL-18. These findings suggest that inflammation plays a key role in the pathologies of both disorders. Studies have suggested that inflammasome activation is associated with the different pathological manifestations of chronic kidney diseases. For instance, proteinuria has been suggested to act as a NLRP3 activator, while calcium carbonate crystal accumulation, a contributor to fibrosis, was also implicated in NLRP3 activation and tubule inflammation [8].

In DKD, studies have suggested that resulting damage to nephrons and increased albumin excretion are the result of elevated levels in the downstream inflammasome-activated cytokines IL-1β and IL-18 [10]. The NLRP3 inflammasome has also been suggested to play a role in the pathology of LN. Accordingly, kidney damage was limited in experiments blocking NLRP3, caspase 1, and IL-18 activation in mouse models of LN [28–31]. Our study supports these findings in humans in that levels of ASC and IL-18 expressions were shown to be significantly elevated in both DKD and LN patients.

In addition to inflammasome activity, our study investigated the levels of other proteins associated with kidney disease and renal function. CRP is a well-established indicator of generalized inflammatory activity and tissue damage [32]. Elevated CRP has been demonstrated in patients with chronic kidney disease, and it has also been implicated in kidney ischemia/reperfusion injury [27, 32]. Here, CRP was elevated in patients with LN but not in DKD. This result is not surprising when considering the different etiologies of the two disorders. Elevated CRP is expected in LN given its role in the complement cascade, and the very close relationship between SLE and the complement system [4, 32].

uPA is produced by tubular epithelial cells, macrophages, and fibroblasts. It has been linked to podocyte function, with increased uAP expression associated with podocyte loss, degradation of renal filtration, and increased proteinuria [33]. It is also thought to play a role in preventing kidney stone formation [34]. In our study, uPA was increased in DKD but not in LN patients, which is consistent with findings in other studies [35].

Serum EGF and Lipocalin-2/NGAL were elevated in DKD and LN. EGF is expressed by cells within the ascending limb of the loop of Henle and the distal tubules and has been shown to have differing effects on renal disease pathology [36]. Lipocalin-2/NGAL is an iron-carrying protein that is expressed by tubular epithelial cells following acute kidney injury and chronic kidney disease [3]. In agreement with our results, other studies have seen increased NGAL expression in patients with LN and DKD [4, 27].
The usefulness of a biomarker is calculated from the ROC to obtain the AUC. The closer to 1 or 100%, the better the biomarker. In addition, the ROC provides the sensitivity and specificity for different cut-off points and associated likelihood ratios to provide the reliability of assays for a particular biomarker. Accordingly, a likelihood ratio above 1 is consistent with a reliable assay, and the higher this value, the more reliability there is. Moreover, a biomarker is also characterized by a PPV and a NPV which are affected by the prevalence of the disease within the cohort studied, and ultimately, one calculates the accuracy of each biomarker to diagnose the disease. Therefore, in this study, to assess the reliability of the above proteins as potential biomarkers for DKD and/or LN, we determined the ROC to obtain the AUC as well as the sensitivity, specificity, PPV, and NPV of all 6 analytes in this study. Of the analytes for DKD, EGF and Lipocalin-2/NGAL showed the best potential for use as biomarkers based on AUC of 0.99 for EGF and 0.96 for NGAL, followed by 0.76 for ASC and 0.75 for uPA. For EGF and Lipocalin-2/NGAL with cut-off points of 27.99 pg/ml and 10,187 pg/ml, respectively, the sensitivity was 100%. For EGF, the specificity was 94%, and for NGAL, it was 83%. Moreover, correlation matrices of the potential biomarkers showed the greatest correlation between EGF and Lipocalin-2/NGAL. In fact, NGAL showed significant positive correlations with IL-18, EGF, uPA, and CRP. Thus, these findings point to Lipocalin-2/NGAL as a key biomarker in DKD, whereas EGF showed significant positive correlations with ASC, IL-18, uPA, and NGAL, suggesting that EGF is a key biomarker in DKD.

Moreover, it is important to identify theragnostic biomarkers that can provide information regarding response to treatment. The involvement of the inflammasome in renal disease offers a viable therapeutic option to treat such diseases. Thus, we propose that ASC and IL-18 can be used as theragnostic biomarkers of therapies targeting the inflammasome in kidney diseases [37].

Moreover, in the DKD cohort, we performed a linear regression analysis to identify the effects of the biomarkers tested on this study on the eGFR. However, we did not detect a statistically significant contribution of any of these biomarkers to eGFR (data not shown), suggesting that the levels of these protein do not affect disease severity, but instead provide information about the inflammatory response associated with the disease. Similarly, a linear regression was carried out to determine the association between the different classifications of LN and these biomarkers (data not shown). However, no statistical significance was found either. Taken together, these data suggest that the proteins ASC, IL-18, uPA, EGF, NGAL, and CRP
contribute significantly to the inflammatory response in renal diseases. However, these proteins do not provide specific clinical information pertaining to the individual pathologies of DKD and LN. Furthermore, future studies should aim at correlating disease severity using individual clinical parameters beyond disease severity to determine whether the potential biomarkers identified in this study can also be used as prognostic biomarkers. In addition, future studies

![ROC curves](image)

**Figure 3:** ROC curve of biomarker proteins in patients with LN. ROC curves indicate the AUC (sensitivity vs 1-specificity) for (a) ASC, (b) IL-18, (c) CRP, (d) uPA, (e) EGF, and (f) Lipocalin-2/NGAL in the serum of patients with LN. ASC: N = 43 C, 28 DKD, 32 LN; IL-18: N = 43 C, 31 DKD, 32 LN; CRP: N = 39 C, 23 DKD, 29 LN; uPA: N = 23 C, 20 DKD, 25 LN; EGF: N = 17 C, 18 DKD, 24 LN; and NGAL: N = 24 C, 14 DKD, 17 LN.

![Correlation matrix](image)

**Figure 4:** Correlation matrix of biomarker proteins in patients with DKD. (a) Plot shows the correlation between ASC, IL-18, CRP, uPA, EGF, and Lipocalin-2/NGAL in the serum of patients with DKD. (b) p values of significance of the Pearson correlation.
should evaluate the effects of anti-inflammatory therapies in the population of DKD and LN patients to identify whether these proteins can be used as theranostic biomarkers.

In this study, the DKD cohort of patients consisted primarily of type II diabetes patients. Importantly, regardless of the type of diabetes, patients used in the DKD cohort presented kidney disease, suggesting that the findings in this project are more likely related to kidney disease due to diabetes than to the type of diabetes. Future studies are needed to compare the levels of these proteins between patients with type I vs. type II diabetes to differentiate whether type I and type II diabetes have different effects on the expression of ASC, IL-18, EGF, and NGAL.

Taken together, our results show that some of the most common proteins associated with kidney disease are reliable biomarkers for DKD and LN. Of these proteins, NGAL was the most reliable indicator in both DKD and LN. In addition, ASC is also a good biomarker in DKD. Further studies will focus on identifying how these biomarkers may change as DKD or LN pathology progresses, and whether they prove to be targets for developing therapies to limit DKD or LN progression. In conclusion, EGF and Lipocalin-2/NGAL proteins specifically associated with renal inflammation are reliable biomarkers for assessing chronic kidney disorders, and should be considered in studies looking at DKD and LN disease progression.

**Data Availability**

The data presented in this study are available on request from the corresponding author.

**Ethical Approval**

The studies involving human participants were reviewed and approved by Schulman Associates IRB.

**Consent**

The patients/participants provided their written informed consent to participate in this study. Donor’s informed consent was provided by those participating in the study Prospective Collection of Samples for Research funded by SeraTrials, LLC., with IRB number 20170439.

**Disclosure**

ZyVersa Therapeutics was not involved in the study design, data collection, analysis and interpretation of data, as well as in the writing of this article or the decision to publish the results.

**Conflicts of Interest**

JPdRV and RWK are cofounders and managing members of InflamaCORE, LLC and have licensed patents on inflammasome proteins as biomarkers of injury and disease as well as on targeting inflammasome proteins for therapeutic purposes. JPdRV and RWK are Scientific Advisory Board Members of ZyVersa Therapeutics. NHJ declares no conflicts of interest. ZyVersa Therapeutics, Inc. has been granted a worldwide exclusive license for development and commercialization of inflammasome inhibitor, IC100, and related products for the treatment of inflammatory diseases, and for companion diagnostics.

**Authors’ Contributions**

Conceptualization was done by JPdRV and RWK. Methodology was done by JPdRV. Formal analysis was done by JPdRV and NHJ. Investigation was done by JPdRV and NHJ. Resources were acquired by JPdRV and RWK. Data curation was done by JPdRV. Writing—original draft preparation, review, and editing were done by NHJ, JPdRV, and RWK. Project administration was done by JPdRV.
Funding acquisition was done by JPdRV and RWK. All authors have read and agreed to the published version of the manuscript.

Acknowledgments

This work was supported by a Sponsored Research agreement from ZyVersa Therapeutics to JPdRV and RWK. We thank Karen Cashmere and Nick LaBella for critically reading the manuscript.

Supplementary Materials

Supplementary Table 1: DKD: ROC curve comparison. Supplementary Table 2: LN: ROC curve comparison. (Supplementary Materials)

References

[1] D. C. Crews, A. K. Bello, G. Saadi, and for the World Kidney - Day Steering Committee, "Burden, access, and disparities in kidney disease," Blood Purification, vol. 48, no. 1, pp. 32–39, 2019.

[2] W. R. Zhang and C. R. Parikh, "Biomarkers of acute and chronic kidney disease," Annual Review of Physiology, vol. 81, no. 1, pp. 309–333, 2019.

[3] S. Lopez-Giacoman and M. Madero, "Biomarkers in chronic kidney disease, from kidney function to kidney damage," World Journal of Nephrology, vol. 4, no. 1, pp. 57–73, 2015.

[4] S. Soliman and C. Mohan, "Lupus nephritis biomarkers," Clinical Immunology, vol. 185, pp. 10–20, 2017.

[5] M. C. Thomas, M. Brownlee, K. Susztak et al., "Diabetic kidney disease," Nature Reviews. Disease Primers, vol. 1, no. 1, p. 15018, 2015.

[6] B. H. Hahn, M. McMahon, A. Wilkinson et al., "American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis," Arthritis Care Res (Hoboken), vol. 64, no. 6, pp. 797–808, 2012.

[7] T. Komada and D. A. Muruve, "The role of inflammasomes in kidney disease," Nature Reviews. Nephrology, vol. 15, no. 8, pp. 501–520, 2019.

[8] H. Xiang, F. Zhu, Z. Xu, and J. Xiong, "Role of inflammasomes in kidney diseases via both canonical and non-canonical pathways," Frontiers in Cell and Development Biology, vol. 8, p. 106, 2020.

[9] F. J. Brand 3rd, M. Forouzandeh, H. Kaur, F. Travascio, and J. P. de Rivero Vaccari, "Acidification changes affect the inflammasome in human nucleus pulposus cells," J Inflamm (Lond), vol. 13, no. 1, p. 29, 2016.

[10] H. L. Hutton, J. D. Ooi, S. R. Holdsworth, and A. R. Kitching, "The NLRP3 inflammasome in kidney disease and autoimmunity," Nephrology (Carlton), vol. 21, no. 9, pp. 736–744, 2016.

[11] S. Adamczak, G. Dale, J. P. de Rivero Vaccari, M. R. Bullock, W. D. Dietrich, and R. W. Keane, "Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome: clinical article," Journal of Neurosurgery, vol. 117, no. 6, pp. 1119–1125, 2012.

[12] N. Kerr, S. W. Lee, J. Perez-Barcena et al., "Inflammasome proteins as biomarkers of traumatic brain injury," PLoS One, vol. 13, no. 12, article e0210128, 2018.

[13] J. Pérez-Bárkca, J. Rodríguez Pilar, O. Salazar et al., “Serum Caspase-1 as an independent prognostic factor in traumatic brain injured patients,” Neurocritical Care, 2021.

[14] J. Pérez-Bárkca, C. Crespi, G. Frontera et al., "Levels of caspase-1 in cerebrospinal fluid of patients with traumatic brain injury: correlation with intracranial pressure and outcome," Journal of Neurosurgery, pp. 1–6, 2021.

[15] N. Kerr, M. Garcia-Contreras, S. Bassi et al., "Inflammasome proteins in serum and serum-derived extracellular vesicles as biomarkers of stroke," Frontiers in Molecular Neuroscience, vol. 11, p. 309, 2018.

[16] S. A. Syed, E. Beurel, D. A. Loewenstein et al., “Defective inflammatory pathways in never-treated depressed patients are associated with poor treatment response,” Neuron, vol. 99, no. 5, pp. 914–924.e3, 2018, e3.

[17] R. W. Keane, W. D. Dietrich, and J. P. de Rivero Vaccari, "Inflammasome proteins as biomarkers of multiple sclerosis," Frontiers in Neurology, vol. 9, p. 135, 2018.

[18] X. O. Scott, M. E. Stephens, M. C. Desir, W. D. Dietrich, R. W. Keane, and J. P. de Rivero Vaccari, "The inflammasome adaptor protein ASC in mild cognitive impairment and Alzheimer’s disease," International Journal of Molecular Sciences, vol. 21, no. 13, p. 4674, 2020.

[19] B. Cyr, R. W. Keane, and J. P. de Rivero Vaccari, "ASC, IL-18 and galectin-3 as biomarkers of non-alcoholic steatohepatitis: a proof of concept study," International Journal of Molecular Sciences, vol. 21, no. 22, p. 8580, 2020.

[20] M. Forouzandeh, J. Besen, R. W. Keane, and J. P. de Rivero Vaccari, "The inflammasome signaling proteins ASC and IL-18 as biomarkers of psoriasis," Frontiers in Pharmacology, vol. 11, p. 1238, 2020.

[21] C. Weaver, B. Cyr, J. C. de Rivero Vaccari, and J. P. de Rivero Vaccari, "Inflammasome proteins as inflammatory biomarkers of age-related macular degeneration," Translational Vision Science & Technology, vol. 9, no. 13, p. 27, 2020.

[22] F. National Kidney, "K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification," American Journal of Kidney Diseases, vol. 39, no. 2, pp. S1–S266, 2002.

[23] J. J. Weening, V. D. D’Agati, M. M. Schwartz et al., "The classification of glomerulonephritis in systemic lupus erythematosus revisited," Kidney International, vol. 65, no. 2, pp. 521–530, 2004.

[24] W. Fierz and X. Bossuyt, "Likelihood ratio approach and clinical interpretation of laboratory tests," Frontiers in Immunology, vol. 12, p. 655262, 2021.

[25] J. A. Hanley and B. J. McNeil, "A method of comparing the areas under receiver operating characteristic curves derived from the same cases," Radiology, vol. 148, no. 3, pp. 839–843, 1983.

[26] L. Li, W. Tang, and F. Yi, "Role of inflammasome in chronic kidney disease," Advances in Experimental Medicine and Biology, vol. 1165, pp. 407–421, 2019.

[27] A. Hashikata, A. Yamashita, S. Suzuki et al., "The inflammation-lipocalin 2 axis may contribute to the development of chronic kidney disease," Nephrology, Dialysis, Transplantation, vol. 29, no. 3, pp. 611–618, 2014.

[28] P. Y. Tsai, S. M. Ka, J. M. Chang et al., "Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation," Free Radical Biology & Medicine, vol. 51, no. 3, pp. 744–754, 2011.
S. M. Ka, J. C. Lin, T. J. Lin et al., "Citral alleviates an accelerated and severe lupus nephritis model by inhibiting the activation signal of NLRP3 inflammasome and enhancing Nrf2 activation," *Arthritis Research & Therapy*, vol. 17, no. 1, p. 331, 2015.

D. Ummarino, "NLRP3 inflammasome ignites podocyte dysfunction," *Nature Reviews Rheumatology*, vol. 13, no. 8, p. 451, 2017.

F. Bonomini, M. Dos Santos, F. V. Veronese, and R. Rezzani, "NLRP3 inflammasome modulation by melatonin supplementation in chronic pristane-induced lupus nephritis," *International Journal of Molecular Sciences*, vol. 20, no. 14, p. 3466, 2019.

J. R. Thiele, J. Zeller, J. Kiefer et al., "A conformational change in C-reactive protein enhances leukocyte recruitment and reactive oxygen species generation in ischemia/reperfusion injury," *Frontiers in Immunology*, vol. 9, p. 675, 2018.

L. Raij, R. Tian, J. S. Wong, J. C. He, and K. N. Campbell, "Podocyte injury: the role of proteinuria, urinary plasminogen, and oxidative stress," *American Journal of Physiology. Renal Physiology*, vol. 311, no. 6, pp. F1308–F1317, 2016.

G. Zhang and A. A. Eddy, "Urokinase and its receptors in chronic kidney disease," *Frontiers in Bioscience*, vol. 13, no. 13, pp. 5462–5478, 2008.

D. D. Qin, D. Song, J. Huang, F. Yu, and M. H. Zhao, "Plasma-soluble urokinase-type plasminogen activator receptor levels are associated with clinical and pathological activities in lupus nephritis: a large cohort study from China," *Lupus*, vol. 24, no. 6, pp. 546–557, 2015.

Y. Isaka, "Epidermal growth factor as a prognostic biomarker in chronic kidney diseases," *Annals of Translational Medicine*, vol. 4, no. 1, p. S62, 2016.

C. Zhang, X. W. Zhu, L. L. Li et al., "A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation," *Diabetes, metabolic syndrome and obesity: targets and therapy*, vol. 12, pp. 1297–1309, 2019.